Last reviewed · How we verify
inhaled tobramycin
Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, killing susceptible bacteria in the lungs.
Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, killing susceptible bacteria in the lungs. Used for Cystic fibrosis with Pseudomonas aeruginosa lung infection, Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients.
At a glance
| Generic name | inhaled tobramycin |
|---|---|
| Sponsor | Seattle Children's Hospital |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Inhaled tobramycin delivers the antibiotic directly to the respiratory tract at high local concentrations. It irreversibly binds to the 30S ribosomal subunit of gram-negative bacteria, preventing accurate translation of mRNA and causing bacterial cell death. This direct lung delivery minimizes systemic exposure while achieving therapeutic concentrations in airway secretions.
Approved indications
- Cystic fibrosis with Pseudomonas aeruginosa lung infection
- Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients
Common side effects
- Cough
- Wheezing
- Dyspnea
- Tinnitus
- Voice alteration
- Bronchospasm
Key clinical trials
- Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial (PHASE2)
- A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (PHASE1, PHASE2)
- Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
- Inhaled Tobramycin in BPD (PHASE1)
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis (PHASE4)
- Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (PHASE3)
- Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution
- A Study of the Clinical Benefit of Tobramycin Inhalation Solution
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inhaled tobramycin CI brief — competitive landscape report
- inhaled tobramycin updates RSS · CI watch RSS
- Seattle Children's Hospital portfolio CI